Effect of diethyldithiocarbamate on anticancer drug toxicity in mice
Author Information
Author(s): I.M. Pannacciulli, R.A. Lerzal, G.V. Bogliolo, M.P. Mencobonil, A.G. Saviane
Primary Institution: University of Genoa
Hypothesis
Can diethyldithiocarbamate reduce the toxicity of doxorubicin, cyclophosphamide, and cis-diamminedichloroplatinum on mice haemopoietic progenitor cells?
Conclusion
Diethyldithiocarbamate reduces the toxicity of doxorubicin, cyclophosphamide, and cis-diamminedichloroplatinum on haemopoietic progenitor cells in mice.
Supporting Evidence
- DDTC reduced the toxic effects of anticancer drugs on bone marrow progenitor cells.
- The protective effect was more evident at lower doses of the anticancer drugs.
- Survival rates of bone marrow CFU-S and GM-CFC were significantly higher with DDTC treatment.
Takeaway
This study found that a substance called diethyldithiocarbamate can help protect mice's blood-making cells from the harmful effects of certain cancer drugs.
Methodology
Mice were injected with anticancer drugs and then with diethyldithiocarbamate, and the survival of bone marrow colony forming units was assessed.
Limitations
The study did not assess the effects of diethyldithiocarbamate in tumor-bearing mice.
Participant Demographics
DBA/2NCrIBR Fl mice, 2-3 months old, both sexes.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website